Clinical trials for 2020-005773-27
The European Union Clinical Trials Register allows you to search for protocol and results information on:
interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
more about the EU Clinical Trials Register
including the source of the information and the legal basis.
The EU Clinical Trials Register currently displays
clinical trials with a EudraCT protocol, of which
are clinical trials conducted with subjects less than 18 years old.
The register also displays information on
older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to
European Guidance 2008/C 168/02
Art. 3 par. 2 and
Commission Guideline 2012/C 302/03,
Art. 5) .
Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the
Clinical Trial Information System
1 result(s) found for: 2020-005773-27.
Displaying page 1 of 1.
EudraCT Number: 2020-005773-27
||Sponsor Protocol Number: APHP190353
||Start Date*: 2021-03-09
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP)
|Full Title: BARIcitinib Cognitive Emotional and Neural signaTuRE
|Medical condition: Patients with rheumatoid arthritis and indication of baricitinib treatment according to a rheumatologist
||Rheumatoid arthritis and other inflammatory polyarthropathies
|Population Age: Adults, Elderly
||Gender: Male, Female
(No results available)
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
Query did not match any studies.
For support, visit the
, log in using your EMA account and open a ticket specifying "EU CTR" in your request.
If you do not have an account, please visit the
page click on "Create an EMA account" and follow the instructions.